, /PRNewswire/ -- Nevro Corp. (NYSE: ), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, announced that on , the Compensation Committee of the Company's Board of Directors granted inducement restricted stock unit awards covering 59,460 shares of Nevro's common stock to twenty-six new non-executive employees to induce them to accept employment with Nevro. Each award was granted under the Nevro Corp.
2023 Inducement Award Plan and vests over a three-year period, subject to continued employment with Nevro through each vesting date. Each award was granted as a material inducement to employment in accordance with the NYSE Listed Company Manual Rule 303A.08.
Nevro routinely posts information that may be important to investors in the "Investor Relations" section of its website at . The company encourages investors and potential investors to consult the Nevro website regularly for important information about Nevro. Headquartered in , Nevro is a global medical device company focused on delivering comprehensive, life-changing solutions that continue to set the standard for enduring patient outcomes in chronic pain treatment.
The company started with a simple mission to help more patients suffering from debilitating pain and developed its proprietary 10 kHz TherapyTM, an evidence-based, non-pharmacologic innovation that has impacted the lives of more than 115,000 patients globally. Nevro's comprehensive HFXTM sp.
